selectIon
SAN DIEGO, CA · Biotechnology · 3 employees
selectION has established an efficient technology platform to develop highly selective peptide blockers for ion channels. Their most advanced drug candidate is si-544 which is a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases. The company is well positioned to expand its range of class-leading ion channelblockers by targeting additional potassium, sodium,
Funding history
- Venture - Series Unknown — $5.4M — Sep 2025
- Venture - Series Unknown — $5.0M — Jun 2023
- Venture - Series Unknown — $5.1M — Apr 2021
- Venture - Series Unknown — $4.1M — May 2019
Recent signals
- Sep 15, 2025: Raised $5.4M in Venture - Series Unknown
- Jun 05, 2023: Raised $5.0M in Venture - Series Unknown
- Apr 08, 2021: Raised $5.1M in Venture - Series Unknown
- May 31, 2019: Raised $4.1M in Venture - Series Unknown
See plans & pricing → Track selectIon’s funding, hiring, and signals — with verified contacts — on Fundz.